# OnCo record mavorixafor (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/mavorixafor/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "mavorixafor" ;
  schema:name "Mavorixafor"@en ;
  schema:alternateName "X4P-001"@en, "AMD-070"@en, "Xolremdi" ;
  schema:description "Mavorixafor is a once-daily tablet that blocks CXCR4, a receptor that traps white cells in the bone marrow. It is approved for the rare immunodeficiency WHIM syndrome and is being tested in Waldenström macroglobulinaemia, where CXCR4 mutations blunt the response to ibrutinib."@en ;
  schema:url <https://onco.cc/drugs/mavorixafor/> ;
  schema:dateModified "2026-09-17"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Mavorixafor> ;
  schema:citation <https://en.wikipedia.org/wiki/Mavorixafor> ;
  onco:status "approved" ;
  onco:tag "subtype-drugs-wave" ;
  onco:modality "Oral CXCR4 antagonist" ;
  onco:approval "US 2024: WHIM syndrome (warts, hypogammaglobulinaemia, infections and myelokathexis) in patients aged 12 and over" ;
  onco:related <https://onco.cc/drugs/ibrutinib/> ;
  onco:cancers <https://onco.cc/cancers/waldenstrom/> ;
  onco:targets <https://onco.cc/targets/cxcr4/> ;
  onco:companies <https://onco.cc/companies/x4-pharmaceuticals/> .